Understanding heparin-induced thrombosis: A brief review

Heparin has been the first line for treatment and prevention of thrombosis for a while. However, one of its non-hemorrhagic effects remains noticeable: heparin-induced thrombocytopenia, mediated by antibodies directed to complexes of platelet factor, and heparin. Binding to platelet FcγRIIA receptor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mariela Irabien-Zúñiga, Edgar A. Rojas-Guerrero, David Gómez-Almaguer
Formato:	article
Lenguaje:	EN ES
Publicado:	Permanyer 2021
Materias:	Thrombosis. Clots. Heparin. Vaccination. Coronavirus disease-19. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8b10f43abc7545de8c709f8758e13e78
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b10f43abc7545de8c709f8758e13e78
record_format	dspace
spelling	oai:doaj.org-article:8b10f43abc7545de8c709f8758e13e782021-11-04T01:10:49ZUnderstanding heparin-induced thrombosis: A brief review10.24875/RMU.210000261665-57962530-0709https://doaj.org/article/8b10f43abc7545de8c709f8758e13e782021-07-01T00:00:00Zhttps://www.medicinauniversitaria.org/frame_esp.php?id=143https://doaj.org/toc/1665-5796https://doaj.org/toc/2530-0709Heparin has been the first line for treatment and prevention of thrombosis for a while. However, one of its non-hemorrhagic effects remains noticeable: heparin-induced thrombocytopenia, mediated by antibodies directed to complexes of platelet factor, and heparin. Binding to platelet FcγRIIA receptors initiates platelet aggregation and its thrombotic effect. Incidence of heparin-induced thrombocytopenia (HIT) ranges from <0.1% to 7%. Diagnosis can be made clinically in patients with thrombocytopenia/thrombosis currently on heparin. Treatment includes suspension of heparin and the administration of non-heparin anticoagulants. Vaccine-induced thrombocytopenia/thrombosis is a complication described after administering vaccines developed to prevent severe coronavirus disease (severe acute respiratory syndrome coronavirus 2). It has a remarkable resemblance to HIT. Therefore, they have been studied clustered. Enzyme-linked immunosorbent assays, a modified platelet-activation test, are used for its diagnosis. Treatment consists of early administration of high-dose intravenous immunoglobulin in conjunction with non-heparin anticoagulation. Mariela Irabien-ZúñigaEdgar A. Rojas-GuerreroDavid Gómez-AlmaguerPermanyerarticleThrombosis. Clots. Heparin. Vaccination. Coronavirus disease-19.Medicine (General)R5-920ENESMedicina Universitaria, Vol 23, Iss 3 (2021)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	Thrombosis. Clots. Heparin. Vaccination. Coronavirus disease-19. Medicine (General) R5-920
spellingShingle	Thrombosis. Clots. Heparin. Vaccination. Coronavirus disease-19. Medicine (General) R5-920 Mariela Irabien-Zúñiga Edgar A. Rojas-Guerrero David Gómez-Almaguer Understanding heparin-induced thrombosis: A brief review
description	Heparin has been the first line for treatment and prevention of thrombosis for a while. However, one of its non-hemorrhagic effects remains noticeable: heparin-induced thrombocytopenia, mediated by antibodies directed to complexes of platelet factor, and heparin. Binding to platelet FcγRIIA receptors initiates platelet aggregation and its thrombotic effect. Incidence of heparin-induced thrombocytopenia (HIT) ranges from <0.1% to 7%. Diagnosis can be made clinically in patients with thrombocytopenia/thrombosis currently on heparin. Treatment includes suspension of heparin and the administration of non-heparin anticoagulants. Vaccine-induced thrombocytopenia/thrombosis is a complication described after administering vaccines developed to prevent severe coronavirus disease (severe acute respiratory syndrome coronavirus 2). It has a remarkable resemblance to HIT. Therefore, they have been studied clustered. Enzyme-linked immunosorbent assays, a modified platelet-activation test, are used for its diagnosis. Treatment consists of early administration of high-dose intravenous immunoglobulin in conjunction with non-heparin anticoagulation.
format	article
author	Mariela Irabien-Zúñiga Edgar A. Rojas-Guerrero David Gómez-Almaguer
author_facet	Mariela Irabien-Zúñiga Edgar A. Rojas-Guerrero David Gómez-Almaguer
author_sort	Mariela Irabien-Zúñiga
title	Understanding heparin-induced thrombosis: A brief review
title_short	Understanding heparin-induced thrombosis: A brief review
title_full	Understanding heparin-induced thrombosis: A brief review
title_fullStr	Understanding heparin-induced thrombosis: A brief review
title_full_unstemmed	Understanding heparin-induced thrombosis: A brief review
title_sort	understanding heparin-induced thrombosis: a brief review
publisher	Permanyer
publishDate	2021
url	https://doaj.org/article/8b10f43abc7545de8c709f8758e13e78
work_keys_str_mv	AT marielairabienzuniga understandingheparininducedthrombosisabriefreview AT edgararojasguerrero understandingheparininducedthrombosisabriefreview AT davidgomezalmaguer understandingheparininducedthrombosisabriefreview
_version_	1718445342641356800

Understanding heparin-induced thrombosis: A brief review

Ejemplares similares